Our Platform for Expedited Drug Discovery and Development Services
The ImQuestSUCCESS platform is utilized at each and every stage of product development to critically evaluate the potential of a test compound and to assure that Efficacy, Toxicity, and Pharmaceutical Properties of a test compound are evaluated in a comprehensive and interactive way. The platform helps to assure that the best clinical product is chosen for continued investment and development. Successful completion of the platform objectives provides significant confidence in the potential of the test compound to transition to human clinical trials. ImQuestSUCCESS empowers us to work smarter, not harder.
As a preclinical CRO we know time is money. The ImQuestSUCCESS platform enhances the robustness of drug development efforts and reduces the risk of expensive clinical development failures by allowing us to exclude candidates which are likely to fail during advanced preclinical and clinical development at early (and less expensive) time points. The ImQuestSUCCESS platform allows the positive selection of those products with the highest probability of clinical success.
The ImQuestSUCCESS platform consists of interrelated efficacy-defining components for cancer (OncoSENS), infectious disease including microbiology and virology (MicroSENS, PrevSENS, ViroSENS), and women's health (FemSENS) with parallel evaluations of in vitro and ex vivo toxicity (ToxiSENS) and the pharmaceutical properties of clinical candidates (PharmaSENS).